A guide to reporting disproportionality analyses – New podcast episode

Research / 07 October 2024

The READUS-PV statement is the first-ever guide for reports of disproportionality analyses that are replicable, reliable, and reproducible.


Disproportionality analyses are a mainstay of pharmacovigilance research, but despite their prevalence are often misinterpreted, misunderstood, and sometimes misguided.

This is why Michele Fusaroli, Daniele Sartori, and their colleagues published the READUS-PV statement, the first-ever guide to reporting disproportionality analyses. Tune in to find out more about these guidelines and how they came to be, the history and overall impact of guidelines in pharmacological research, and what it means to publish "good" pharmacovigilance science.

Subscribe by visiting the Drug Safety Matters website.

You may also like


Mind the gap: Preventing medication errors after hospital discharge

Medication errors are a key pharmacovigilance issue, especially as patients transition between secondary and primary care as they readjust to life outside of hospital.

Research / 09 September 2024

Weeding out duplicates to better detect side-effects – New podcast episode

Duplicate reports are a big problem when it comes to signal detection, but with the help of machine learning and new ways of comparing reports, we may more effectively detect them.

Research / 26 August 2024

Artificial intelligence in pharmacovigilance: Harnessing potential, navigating risks

AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.

Research / 22 October 2024